Metabolism has always been a crucial pillar in cancer treatment, but clinical considerations have been limited to general diet and nutrition advice, minimizing the potential therapeutic impact of ...
Figure 1: Key signaling pathways and targeted factors in dysregulated BC. This figure illustrates the major signaling pathways and their intricate crosstalk in BC, focusing on the GPCR, RTKs, ...
UIC researchers have successfully repurposed an FDA-approved cancer drug, doxorubicin, to treat drug-resistant strains of ...
The tumor tissue-based real-time PCR kit will be used to identify patients with PIK3CA gene mutations eligible for treatment with PI3K inhibitor.
CDK 4/6 inhibitors (CDK4/6i) remain part of the standard first-line treatment for patients with hormone receptor–positive metastatic breast cancer, offering demonstrable improvements in both ...
Hutchmed begins global clinical trial of PI3K/PIKK-EGFR ATTC candidate HMPL-A580 in patients with solid tumours: Hong Kong, Shanghai Friday, March 6, 2026, 10:00 Hrs [IST] Hutchme ...
Oral presentation of Ph 1a clinical data highlights potential best-in-class drug profile in heavily pretreated patients with PI3Ka-mutant ...
Please provide your email address to receive an email when new articles are posted on . Low-dose aspirin significantly reduced risk for colorectal cancer recurrence among patients with mutations in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results